SESSION LECTURE

No. 55

Neurodegenerative Diseases: From Biology to Clinical Applications

Room: 406

Co-Chairs: Jiawei Zhou

Claude Wischik

Day 3 October 29th (Monday) 8:30 – 12:00		
Time	**Speaker**	**Title**
8:30-9:00	**Claude Wischik** *The University of Aberdeen, UK*	Hydromethylthionine: potential of a single drug for multiple neurodegenerative protein aggregation disorders
9:00-9:30	**Jing Zhang** *University of Washington, USA*	Microvesicles, a new hot spot in neurodegenerative investigation
9:30-10:00	**Yong Shen** *University of Science and Technology of China, China*	A novel mechanism of cerebral amyloid angiopathy (CAA)
10:00-10:30	**Tea Break**	
10:30-11:00	**Boxun Lu** *Fudan University, China*	Allele-selective Degradation of Mutant HTT (mHTT) via Autophagy by mHTT-LC3 Linker Compounds
11:00-11:30	**Eun-Hye Joe** *Ajou Unversity, Korea*	Roles of brain inflammation in acutely injured brain
11:30-12:00	**Jiawei Zhou** *Institute of Neuroscience, Chinese Academy of Sciences, China*	Role of NG2 glia-mediated signaling in the suppression of neuroinflammation

Jiawei Zhou

jwzhou@ion.ac.cn

Professor Zhou is currently a Senior Investigator in the Institute of Neuroscience, Chinese Academy of Sciences and Director of the State Key Laboratory of Neuroscience. His research focus on the molecular and cellular mechanisms underlying the maintenance of immune homeostasis in the CNS and the regulation of dopaminergic neurotransmission in mammals.

Claude Wischik

cmw@taurx.com

Professor Wischik holds the Chair in Mental Health at the University of Aberdeen in Scotland, and is Executive Chairman of TauRx Pharmaceuticals. His team discovered the first pharmaceutically viable Tau Aggregation Inhibitor (TAI) as a potential treatment for AD. Their current basic research focuses on the broader potential for protein aggregation inhibitors in other neurodegenerative disorders, discovery of third generation compounds.

Yong Shen

yongshen@ustc.edu.cn

Distinguished professor of Neurobiology and Neurology at the University of Science and Technology of China. The aims of his research are to understand molecular and cellular mechanisms underlying how amyloid protein is generated in the cerebral vessels and what molecules or what enzymatic process cause cerebral vascular cell degeneration, and how surrounding neurons are injured, which ultimately results in dementia.

Eun-Hye Joe

ehjoe@ajou.ac.kr

Professor Joe's research is focused on behavior and function of glial cells and blood cells in injured brain from injury to repair, and how Parkinson's disease genes affect their functions. She has worked on astrocytes and microglia in intact and injured brain since 1995, and her lab was selected as National Research Lab of Brain Inflammation at 2008. She is the Chair of the Department of Pharmacology since 2009.

Jing Zhang

zhangj@uw.edu

Prof. Zhang's research is centered on neurodegenerative disorders, especially Parkinson's disease and Alzheimer's disease. He is particularly interested in translational medicine, with biomarker discovery and validation as the major emphasis. More recently, Prof. Zhang's group has progressed to discovering bloodbased but CNS specific biomarkers by pioneering a novel technology.

Boxun Lu

luboxun@fudan.edu.cn

Professor Lu focuses on translational research of neurodegenerative disorders, especially polyQ diseases such as Huntington's Disease. He has developed several novel chemical biology and highthroughput technologies to identify potential therapeutic targets and candidate compound drugs for Huntington's Disease.